[Mesenchymal stem cell-derived exosomes: a new hope for metabolic-associated fatty liver disease]

Currently, there are clinically limited therapeutic options for metabolic-associated fatty liver disease (MAFLD), and the treatment effect is not optimistic. Mesenchymal stem cell (MSC) therapy for MAFLD shows good application prospects but also possesses certain potential treatment risks. Mesenchymal stem cells can secrete various functional exosomes, which not only retain the therapeutic efficacy of mesenchymal stem cells but also significantly mitigate their associated treatment risks. Mesenchymal stem cell-derived exosomes can play a hepatoprotective, antioxidant, or drug-sensitizing role in liver diseases, with advantages of low immunogenicity and high biocompatibility. Therefore, mesenchymal stem cell-derived exosomes are expected to offer novel therapeutic strategies for the treatment of metabolic-associated fatty liver disease.